CMS Makes Medicare Drug Price Negotiation Rules Permanent

CMS has finalized a rule that makes its Medicare Drug Price Negotiation Program framework permanent, moving the program from year-by-year guidance toward a fixed, repeatable process. The rule sets ongoing policies for future negotiation cycles, beginning with prices that take effect in 2029, according to a Nov. 5 news release cited by Becker's Hospital Review.

The program, created under the Inflation Reduction Act, lets Medicare negotiate prices directly with manufacturers for selected high-spend drugs. CMS said the permanent framework is meant to give drugmakers a clearer and more predictable path through each round, replacing the shifting rules that defined the first cycles.

In practice, manufacturers, payers, and providers now have a stable rulebook to plan around instead of guessing how each cycle's terms might change. That predictability matters for pricing strategy, contracting, and formulary decisions tied to negotiated drugs. CMS signaled it will keep refining details through future guidance, so the core structure is locked while specifics can still evolve.